U.S. Markets closed
  • S&P 500

    3,693.23
    -64.76 (-1.72%)
     
  • Dow 30

    29,590.41
    -486.27 (-1.62%)
     
  • Nasdaq

    10,867.93
    -198.88 (-1.80%)
     
  • Russell 2000

    1,679.59
    -42.72 (-2.48%)
     
  • Crude Oil

    79.43
    -4.06 (-4.86%)
     
  • Gold

    1,651.70
    -29.40 (-1.75%)
     
  • Silver

    18.78
    -0.76 (-3.90%)
     
  • EUR/USD

    0.9693
    -0.0145 (-1.4733%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • Vix

    29.92
    +2.57 (+9.40%)
     
  • GBP/USD

    1.0857
    -0.0398 (-3.5360%)
     
  • USD/JPY

    143.3300
    +0.9950 (+0.6991%)
     
  • BTC-USD

    19,136.69
    +247.39 (+1.31%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    27,153.83
    -159.30 (-0.58%)
     

Credit Suisse Lifts Price Targets For Drug Distributors After Solid Q2 Performance

·1 min read
  • Credit Suisse raised the price target on Cigna Corporation (NYSE: CI) from $315 to $329. The analyst raised the EPS estimate for 2022/2023 to $22.95/25.30.

  • Credit Suisse notes that despite the positive trends experienced in 1H22, Cigna maintains a prudent outlook for the rest of the year.

  • The management noted that, while utilization came in favorable in 2Q22, the company is not extrapolating this to 2H22 and is expecting a more normal utilization pattern, in-line with historical norms.

  • Credit Suisse beefed up the price target for McKesson Corporation (NYSE: MCK) from $377 to $385.

  • The company highlighted good performance across the board in the quarter, driven in part by higher Covid contributions and strength from national account partners.

  • The company expects the extended government Covid contract contribution to be evenly split between quarters for the life of the agreement.

  • Credit Suisse raised the price target for CVS Health Corp (NYSE: CVS) to $117 from $113, including higher utilization and worsening macroeconomic conditions. See the Q2 earnings.

  • CVS focuses on M&A in primary care, home health, and physician enablement. CVS sees physician enablement as working with providers to enable them to bear risk.

  • Home care offers considerable opportunity in the digital age and is important in coordinating patient care.

Latest Ratings for CI

Date

Firm

Action

From

To

Mar 2022

Mizuho

Maintains

Buy

Feb 2022

SVB Leerink

Maintains

Market Perform

Feb 2022

Morgan Stanley

Maintains

Equal-Weight

View More Analyst Ratings for CI

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.